Clinical Trial Update: A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer [Phase 3]

View source ↗

Summary

Phase 3 study of donafenib in radioiodine-refractory differentiated thyroid cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• Donafenib (donafenib)

Snippet

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Conditions: Differentiated Thyroid Cancer | Phase 3 | Status: TERMINATED